Trimethylamine-N-oxide and 5-year mortality: the role of gut microbiota-generated metabolite from the CORE-Thailand cohort
Vichai Senthong,Songsak Kiatchoosakun,Chaiyasith Wongvipaporn,Jutarop Phetcharaburanin,Piyamitr Sritara,Arintaya Phrommintikul,CORE Investigators,Sukit Yamwong,Suphot Srimahachota,Smonporn Boonyaratavej,Sudarat Satitthummanid,Vorarit Lertsuwunseri,Kamol Udol,Rungroj Krittayaphong,Thananya Boonyasirinant,Nattawut Wongpraparut,Kasem Rattanasumawong,Waraporn Tiyanon,Bancha Satirapoj,Swangjit Suraamornkul,Chanikarn Kanaderm,Pornwalee Porapakkham,Siribha Changsirikulchai,Pisit Hutayanon,Chaicharn Deerochanawong,Wattana Wongtheptien,Sasivimon Jai-Aue,Mongkol Maraprasertsak,Thanakorn Laksomya,Pailin Paspitsanu,Wanwarang Wongcharoen,Narawudt Prasertwitayakij,Supawan Buranapin,Kanokwan Watcharasaksilp,Uthai Phengtham,Yotsawee Chotechuang,Khanchai Siriwattana,Kamonwan Siriaree,Jitti Kositchaiwat,Pakaphan Dinchuthai,Bancha Sukanandachai,Tanin Simtharakaew,Pyatat Tatsanaviva,Prawit Taweesangsuksakul,Saranyou Suwanugsorn,Sirichai Cheewatanakornkul,Sarawut Suksuphew,Somchai Dutsadeevettakul,Surapong Worasuwannarak
DOI: https://doi.org/10.1038/s41598-024-71479-z
2024-09-11
Abstract:The gut microbiota metabolite trimethylamine-N-oxide (TMAO)-derived from dietary phosphatidylcholine-is mechanistically linked to cardiovascular disease (CVD) and increased cardiovascular risk. This study examined the relationship between fasting plasma TMAO levels and 5-year all-cause mortality in a cohort of patients at high risk of cardiovascular events (CORE-Thailand Registry). Of the 134 patients, 123 (92%) had established cardiovascular disease, and 11 (8%) had multiple risk factors. Fasting plasma TMAO levels were measured using nuclear magnetic resonance spectroscopy. Within this prospective cohort study, the median TMAO was 3.81 μM [interquartile range (IQR) 2.89-5.50 μM], with a mean age of 65 ± 11 years; 61% were men, and 39.6% had type II diabetes. Among 134 patients, 65 (49%) were identified as the high-TMAO group (≥ 3.8 μM), and 69 (51%) were identified as the low-TMAO group (< 3.8 μM). After a median follow-up of 58.8 months, the high-TMAO group was associated with a 2.88-fold increased mortality risk. Following adjustment for traditional risk factors, high-sensitivity cardiac troponin-T, estimated glomerular filtration rate, angiotensin-converting enzyme (ACEI), or angiotensin-receptor blocker (ARB) use, the high-TMAO group remained predictive of 5-year all-cause mortality risk (the high-TMAO vs. the low-TMAO group, adjusted hazard ratio 2.73, 95% CI 1.13-6.54; P = 0.025). Among Thai patients at high risk of cardiovascular events, increased plasma TMAO levels portended greater long-term mortality risk.